Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?
- PMID: 34890628
- PMCID: PMC8882444
- DOI: 10.1016/j.mbs.2021.108754
Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?
Abstract
Finding the causative pathophysiological mechanisms for Parkinson's disease (PD) is important for developing therapeutic interventions. Until recently, it was believed that Lewy bodies (LBs), the hallmark of PD, are mostly composed of alpha-synuclein (α-syn) fibrils. Recent results (Shahmoradian et al. (2019)) demonstrated that the fibrillar form of α-syn is lacking from LBs. Here we propose that this surprising observation can be explained by the catalytic activity of the fibrillar form of α-syn. We assumed that α-syn fibrils catalyze the formation of LBs, but do not become part of them. We developed a mathematical model based on this hypothesis. By using the developed model, we investigated the consequences of this hypothesis. In particular, the model suggests that the long incubation time of PD can be explained by a two-step aggregation process that leads to its development: (i) aggregation of monomeric α-syn into α-syn oligomers and fibrils and (ii) clustering of membrane-bound organelles, which may cause disruption of axonal trafficking and lead to neuron starvation and death. The model shows that decreasing the rate of destruction of α-syn aggregates in somatic lysosomes accelerates the formation of LBs. Another consequence of the model is the prediction that removing α-syn aggregates from the brain after the aggregation of membrane-bound organelles into LBs has started may not stop the progression of PD because LB formation is an autocatalytic process; hence, the formation of LBs will be catalyzed by aggregates of membrane-bound organelles even in the absence of α-syn aggregates. The performed sensitivity study made it possible to establish the hierarchy of model parameters with respect to their effect on the formation of vesicle aggregates in the soma.
Keywords: Alpha-synuclein; Axon; Mathematical modeling; Neuron; Parkinson’s disease.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures














References
-
- Jankovic J, Parkinson’s disease: Clinical features and diagnosis, Journal of Neurology Neurosurgery and Psychiatry 79 (2008) 368–376. - PubMed
-
- Charvin D, Medori R, Hauser RA, Rascol O, Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs, Nature Reviews Drug Discovery 17 (2018) 804–822. - PubMed
-
- Kalia LV, Lang AE, Parkinson’s disease, Lancet 386 (2015) 896–912. - PubMed
-
- Fares MB, Jagannath S, Lashuel HA, Reverse engineering Lewy bodies: How far have we come and how far can we go? Nature Reviews Neuroscience 22 (2021) 111–131. - PubMed
-
- Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, Castano-Diez D, Schweighauser G, Graff-Meyer A, Godie KN, Sutterlin R, Huisman E, Ingrassia A, de Gier Y, Rozemuller AJM, Wang J, De Paepe A, Erny J, Staempfli A, Hoernschemeyer J, Grosserueschkamp F, Niedieker D, El-Mashtoly SF, Quadri M, Van IJcken WFJ, Bonifati V, Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, Van de Berg WDJ, Lauer ME, Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes, Nature Neuroscience 22 (2019) 1099–1109. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous